Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-445-4 | CAS number: 3896-11-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 968
- Report date:
- 1968
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 969
- Report date:
- 1969
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- (no neurobehavioural assessment and no detailed clinical examinations, no ophthalmoscopic examinations)
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Bumetrizole
- EC Number:
- 223-445-4
- EC Name:
- Bumetrizole
- Cas Number:
- 3896-11-5
- Molecular formula:
- C17 H18 Cl N3 O
- IUPAC Name:
- 2-tert-butyl-6-(5-chloro-2H-benzotriazol-2-yl)-4-methylphenol
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): CH 3504
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Central Instititute for Nutrition and Food Research colony
- Age: Weanling rats
- Weight at study initiation: males, 45 - 64 g; females 45 - 62 g
- Housing: Wire screen cages (5 to a cage)
- Diet: ad libitum
- Water: ad libitum
- Acclimation: no data
ENVIRONMENTAL CONDITIONS: no data
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): every 2 weeks
- Mixing appropriate amounts with stock diet (see table 1 for composition)
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 25 mg/kg bw/day (actual dose received)
- Remarks:
- males (dose equivalent to 400 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 62 mg/kg bw/day (actual dose received)
- Remarks:
- males (dose equivalent to 1000 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 153.9 mg/kg bw/day (actual dose received)
- Remarks:
- males (dose equivalent to 2500 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 637.4 mg/kg bw/day (actual dose received)
- Remarks:
- males (dose equivalent to 10,00 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 28.9 mg/kg bw/day (actual dose received)
- Remarks:
- females (dose equivalent to 400 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 70.6 mg/kg bw/day (actual dose received)
- Remarks:
- females (dose equivalent to 1000 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 176 mg/kg bw/day (actual dose received)
- Remarks:
- females (dose equivalent to 2500 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- Dose / conc.:
- 740.1 mg/kg bw/day (actual dose received)
- Remarks:
- females (dose equivalent to 10,00 ppm nominal concentration. Calculated by average food consumption and average body weights after 13 weeks)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes; mortality and abnormalities in condition and behaviour
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: once per week
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, but as g food/rat/day
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
- Time schedule for examinations: in the fisrt 4 weeks and then in week 11 and 12
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 12th week
- Anaesthetic used for blood collection: no data
- Animals fasted: no data
- How many animals: all animals
- Parameters checked in table No. 2 were examined.
CLINICAL CHEMISTRY: Yes
- How many animals: 5 animals/sex/dose
- Parameters checked: glutamic pyruvic transaminase (SGPT), glutamic oxalo-acetic transaminase (SGOT) and alkaline phosphatase (SAP), glucose-6-phosphatase (G6Pase) and glucose-6- phosphate dehydrogenase (G6PD).
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- Organ weight: heart, liver, kidney, spleen, testicle/ovary, thymus, pituitary, thyroid and adrenal
HISTOPATHOLOGY: Yes
- How many animals: all animals of the control and high dose groups
- Parameters checked: heart, *liver, *kidney, spleen, testicle/ovary, thymus, pituitary, *thyroid and adrenal, lung, salivary glands (sub-maxillary, sub-lingual and parotid), prostate, epididermis, coagulating gland, seminal vesicle, trachea, oesophagus, thoracic aorta, spinal cord, femoral nerve, skeletal muscle, uterus, preputial gland, external lacrimal gland, fore- and glandular stomach, duodenum, ileum, caecum, mandibular and mesenteric lymph nodes, pancreas, urinary bladder, skin and bone marrow (sternum).
*checked in the 400, 1000 and 2500 ppm dose groups
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No deaths occurred and no abnormalities in condition or behaviour were observed.
BODY WEIGHT AND WEIGHT GAIN: There were no significant differences between the treated and control rats.
FOOD CONSUMPTION AND COMPOUND INTAKE: There was no compound effect at any of the dosing intervals.
FOOD EFFICIENCY: There was no compound effect at any of the dosing intervals.
HAEMATOLOGY: The haemoglobin content and packed cell volume of males were slightly, though significantly (p < 0.01) decreased at the 1000, 2500, and 10000 ppm feeding levels by 6, 6.6 and 5.4% compared to controls for haemaglobin content and at 2500 and 10000 ppm feeding levels by 5.6 and 5.1% compared to control for packed cell content. At the respective lower feeding levels these effects were not observed. These small differences did not show a dose relationship. In females, such effects were not seen. Therefore the low values in males are not explained as compound effects but rather as the result of relatively high values in male controls except for a slight decrease in haemoglobin content at 0.1% females, however, no distinct differences in haematological data between the treated and control rats were noticed.
CLINICAL CHEMISTRY: The alkaline phosphatase activity of females was slightly decreased at the highest feeding level. A trend towards lower SAP activity with increasing levels of the compound was not observed. A slight increase in G6Pase activity at the two highest levels in either sex was noticed.
ORGAN WEIGHTS: None of the organs showed considerable differences between groups. Relative weights of liver and kidney in percent of body weight were slighly increased at the highest feeding level. The difference was significant in females only. Kidney increased by 6% conpared to controls (p < 0.05) and liver increased by 10.7% compared to controls (p < 0.01).
GROSS PATHOLOGY: Gross autopsy findings were essentially negative.
HISTOPATHOLOGY: NON-NEOPLASTIC: No changes were fond in spleen, brain, testicle, epididymis, ovary, thymus, pituitary, submaxillary and partotid gland, seminal vesicle, coagulating gland, aorta, spinal cord, femoral nerve, oesophagus, stomach, duodenum, ileum, manibular and mesenteric lymph nodes, uterus, skin and bone marrow. The abnormalities that were found in liver, kidneys, thyroid, lungs, trachea, heart, bladder, caecum, colon, sublingual muscle, preputial gland and prostate are common findings in the strain of rat used. Some of the abnormalities, e.g. nephrocalcinosis in kidneys, activated appearance of the thyroid gland and interstitial pneumonitis (lung) occurred more frequently and to a distinctly higher degree in one or several test groups than in the control group. However, the incidence of all three phenomena in the control group was strikingly low and, moreover, their severity in treated animals was not dose-dependent. Therefore, none of the histopathological changes observed may be ascribed to the ingestion of the test substance.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- (systemic)
- Effect level:
- ca. 637 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: corresponding to 10000 ppm in diet. No adverse effects seen in any parameter at the highest dose level tested.
- Dose descriptor:
- NOAEL
- Remarks:
- (systemic)
- Effect level:
- ca. 740 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: corresponding to 10000 ppm in diet. No adverse effects seen in any parameter at the highest dose level tested.
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
Table 3: Average body weights (g) after 12 weeks
|
|
Week |
||||||
|
|
0 |
2 |
4 |
6 |
8 |
10 |
12 |
|
Concentration |
|
|
|
|
|
|
|
Male |
0 |
52.6 |
111.6 |
179.2 |
235.4 |
271.6 |
292.6 |
311.6 |
400 |
52.8 |
113.8 |
182.6 |
239.3 |
274.6 |
291.3 |
310.3 |
|
1000 |
52.6 |
117.8 |
193 |
254.3 |
287.5 |
309.1 |
331 |
|
2500 |
52.9 |
115.1 |
184.6 |
249.2 |
284.7 |
304.6 |
328.1 |
|
10000 |
53 |
111 |
176.9 |
235 |
272.6 |
293.9 |
313.2 |
|
|
|
|
|
|
|
|
|
|
Female |
0 |
51.2 |
97.3 |
129.2 |
152.8 |
170.6 |
182.3 |
186.1 |
400 |
51.1 |
100.3 |
131.2 |
154.7 |
170 |
182.7 |
189.6 |
|
1000 |
51 |
96.9 |
126.6 |
151 |
169.7 |
181.7 |
187.9 |
|
2500 |
51 |
98.2 |
130.5 |
154.4 |
172.2 |
184.3 |
192 |
|
10000 |
50.9 |
94.8 |
130.5 |
158.3 |
175 |
185.4 |
193.7 |
Table 4: Average food consumption in g/rat/day after 12 weeks and food efficiency
|
Average food consumption |
|
Food efficiency |
|||||||
|
Week |
|
weeks |
|||||||
|
|
1 |
2 |
3 |
4 |
11 |
12 |
|
1 to 4 |
11 + 12 |
Male |
0 |
8.3 |
11.8 |
14.3 |
16.5 |
16.2 |
16.5 |
|
0.35 |
0.08 |
400 |
8.3 |
13 |
14.9 |
17.4 |
15.8 |
18.7 |
|
0.35 |
0.08 |
|
1000 |
8.8 |
12.8 |
15.8 |
18.2 |
16.4 |
17.9 |
|
0.36 |
0.09 |
|
2500 |
8.7 |
12.5 |
15.4 |
17.4 |
16.4 |
17.3 |
|
0.35 |
0.10 |
|
10000 |
8.3 |
12.4 |
14.8 |
16.8 |
17 |
17.6 |
|
0.34 |
0.08 |
|
|
|
|
|
|
|
|
|
|
|
|
Female |
0 |
7.7 |
10.2 |
11 |
11.3 |
10.6 |
10.5 |
|
0.28 |
0.03 |
400 |
8.6 |
11.1 |
12.1 |
12.2 |
11.3 |
11.7 |
|
0.26 |
0.04 |
|
1000 |
8 |
10.6 |
11.4 |
11.7 |
11.9 |
10.9 |
|
0.26 |
0.04 |
|
2500 |
7.9 |
11.1 |
11.9 |
12 |
11.1 |
11.6 |
|
0.27 |
0.05 |
|
10000 |
7.7 |
11 |
12.9 |
13 |
12.3 |
12.5 |
|
0.25 |
0.05 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)